What is apixaban and what are the side effects?
Written by Cerner Multum. What is apixaban? Apixaban is used to lower the risk of stroke caused by a blood clot in people with a heart rhythm disorder called atrial fibrillation.
What was the objective of the apixaban study?
The objective of this study was to quantify the degree of INR elevation in hospitalized patients receiving apixaban. This was a single-center, retrospective, observational analysis of adult patients who received at least 1 dose of apixaban during their hospital admission and had at least 1 INR sample collected prior to and following administration.
What are some peri-procedural management of apixaban?
Suggestions for Peri-Procedural Management of Apixaban. 1 ASRA 4th edition 2018: hold 72 hours for all patients prior to neuraxial procedures, without consider of the effect of renal function on elimination half-life and clearance.
How is apixaban used to treat atrial fibrillation?
Apixaban is used to lower the risk of stroke caused by a blood clot in people with a heart rhythm disorder called atrial fibrillation. Apixaban is also used after hip or knee replacement surgery to prevent a type of blood clot called deep vein thrombosis (DVT), which can lead to blood clots in the lungs (pulmonary embolism).
Why was apixaban used in the Caravaggio trial?
In the Caravaggio trial, we wanted to assess whether oral apixaban would be noninferior to subcutaneous dalteparin, a low-molecular-weight heparin, for the prevention of recurrent venous thromboembolism in patients with cancer without increasing the risk of major bleeding.
How are apixaban tablets used to treat stroke?
Apixaban tablets are indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Apixaban tablets are indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
What is the steady state of apixaban pharmacokinetics?
Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients J Am Soc Nephrol. 2017 Jul;28(7):2241-2248.doi: 10.1681/ASN